Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Elena V Varlamov in
Google Scholar
PubMed
Search for other papers by Dan Alexandru Niculescu in
Google Scholar
PubMed
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Swechya Banskota in
Google Scholar
PubMed
Search for other papers by Simona Andreea Galoiu in
Google Scholar
PubMed
Search for other papers by Catalina Poiana in
Google Scholar
PubMed
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Introduction Acromegaly is a rare disease that is caused by excessive growth hormone (GH) secretion by a pituitary adenoma ( 1 , 2 , 3 ). The clinical picture of active acromegaly is characterized by a combination of symptoms, signs, and
Search for other papers by Natalie Rogowski-Lehmann in
Google Scholar
PubMed
Search for other papers by Aikaterini Geroula in
Google Scholar
PubMed
Search for other papers by Aleksander Prejbisz in
Google Scholar
PubMed
Search for other papers by Henri J L M Timmers in
Google Scholar
PubMed
Search for other papers by Felix Megerle in
Google Scholar
PubMed
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Search for other papers by Stephanie M J Fliedner in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Anthony Stell in
Google Scholar
PubMed
Search for other papers by Andrzej Januszewicz in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
PPGLs are caused by the excessive production of catecholamines and include headache, palpitations and sweating together with intermittently or persistently elevated blood pressure ( 5 ). While the presence of typical signs and symptoms has some
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
Search for other papers by Richard P Steeds in
Google Scholar
PubMed
Search for other papers by Vandana Sagar in
Google Scholar
PubMed
Search for other papers by Shishir Shetty in
Google Scholar
PubMed
Search for other papers by Tessa Oelofse in
Google Scholar
PubMed
Search for other papers by Harjot Singh in
Google Scholar
PubMed
Search for other papers by Raheel Ahmad in
Google Scholar
PubMed
Search for other papers by Elizabeth Bradley in
Google Scholar
PubMed
Search for other papers by Rachel Moore in
Google Scholar
PubMed
Search for other papers by Suzanne Vickrage in
Google Scholar
PubMed
Search for other papers by Stacey Smith in
Google Scholar
PubMed
Search for other papers by Ivan Yim in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Yasir S Elhassan in
Google Scholar
PubMed
Search for other papers by Hema Venkataraman in
Google Scholar
PubMed
Search for other papers by John Ayuk in
Google Scholar
PubMed
Search for other papers by Stephen Rooney in
Google Scholar
PubMed
Department of Hepatology and Liver Transplantation, University Hospitals Birmingham (Queen Elizabeth), NHS Hospitals Foundation Trust, Birmingham, UK
Search for other papers by Tahir Shah in
Google Scholar
PubMed
heart (around 90% of cases), likely due to pulmonary inactivation of the vasoactive substances, resulting in right heart failure. Presentation, clinical assessment and diagnosis Cardiac symptoms and signs are often lacking or are subtle until CHD
Search for other papers by Natasha Bergmann in
Google Scholar
PubMed
Search for other papers by Søren Ballegaard in
Google Scholar
PubMed
Search for other papers by Pernille Holmager in
Google Scholar
PubMed
Search for other papers by Per Bech in
Google Scholar
PubMed
Search for other papers by Åke Hjalmarson in
Google Scholar
PubMed
Search for other papers by Finn Gyntelberg in
Google Scholar
PubMed
Department of Endocrinology, Ull Care A/S, Psychiatric Research Unit, The Cardiovascular Institute, The National Research Center for the Working Environment, Faculty of Health and Medical Sciences, Herlev University Hospital, Herlev, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Introduction The risk of depression in people with diabetes is two times higher when compared with patients without diabetes, and major depression and elevated depressive symptoms have been found to be present in 11 and 31%, respectively, of
Search for other papers by Raluca Maria Furnica in
Google Scholar
PubMed
Search for other papers by Muhammad Muddaththir Dusoruth in
Google Scholar
PubMed
Search for other papers by Alexandre Persu in
Google Scholar
PubMed
Search for other papers by Damien Gruson in
Google Scholar
PubMed
Search for other papers by Michel Mourad in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
myocardial syndrome or chronic hypertrophic or dilated cardiomyopathy ( 4 ). For decades, the diagnosis of PPGL has been most commonly based on the presence of paroxysmal or sustained hypertension, associated with suggestive symptoms and signs such as
Search for other papers by I M A A van Roessel in
Google Scholar
PubMed
Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
Endo-ERN European Reference Network on Rare endocrine conditions
Search for other papers by J P de Graaf in
Google Scholar
PubMed
Endo-ERN European Reference Network on Rare endocrine conditions
Search for other papers by N R Biermasz in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
Search for other papers by E Charmandari in
Google Scholar
PubMed
Search for other papers by H M van Santen in
Google Scholar
PubMed
treatment for a brain tumor is a rare disease and patients may encounter difficulties in receiving optimal health care. Delay in recognition of signs and symptoms, difficulties in timely referral or assigning the correct treatment may occur. HD can have
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Ken K Y Ho in
Google Scholar
PubMed
Search for other papers by Bradley S Miller in
Google Scholar
PubMed
Search for other papers by Ignacio Bergada in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
GHD to severe GH resistance ( 8 ). Thus, establishing the diagnosis of GHD can be challenging in children and adults. Although short stature and growth faltering are useful clinical markers for GHD in children, signs and symptoms of adult subjects with
Search for other papers by Kinnaree Sorapipatcharoen in
Google Scholar
PubMed
Search for other papers by Thipwimol Tim-Aroon in
Google Scholar
PubMed
Search for other papers by Pat Mahachoklertwattana in
Google Scholar
PubMed
Search for other papers by Wasun Chantratita in
Google Scholar
PubMed
Search for other papers by Nareenart Iemwimangsa in
Google Scholar
PubMed
Search for other papers by Insee Sensorn in
Google Scholar
PubMed
Search for other papers by Bhakbhoom Panthan in
Google Scholar
PubMed
Search for other papers by Poramate Jiaranai in
Google Scholar
PubMed
Search for other papers by Saisuda Noojarern in
Google Scholar
PubMed
Search for other papers by Patcharin Khlairit in
Google Scholar
PubMed
Search for other papers by Sarunyu Pongratanakul in
Google Scholar
PubMed
Search for other papers by Chittiwat Suprasongsin in
Google Scholar
PubMed
Search for other papers by Manassawee Korwutthikulrangsri in
Google Scholar
PubMed
Search for other papers by Chutintorn Sriphrapradang in
Google Scholar
PubMed
Search for other papers by Preamrudee Poomthavorn in
Google Scholar
PubMed
either confirmatory test for positive newborn screening (NBS) or thyroid function tests for other signs and symptoms suggesting CH. Patients with transient CH secondary to maternal conditions, sick euthyroid syndrome and obvious syndromic features were
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
School of Nursing and Midwifery, Institute of Clinical Sciences, University of Birmingham, UK
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by Andrew A Toogood in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Neil Gittoes in
Google Scholar
PubMed
Search for other papers by Anne Topping in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Niki Karavitaki in
Google Scholar
PubMed
–6 months of stopping treatment, and 9% ( n = 6) would carry out patient review within 12 months. On this review, the majority ( n = 33–54) would complete anthropometric, biochemical, QoL and signs/symptoms monitoring. None of the respondents specified the
Search for other papers by Yi Wang in
Google Scholar
PubMed
Search for other papers by Yingying Xu in
Google Scholar
PubMed
Search for other papers by Rongrong Xie in
Google Scholar
PubMed
Search for other papers by Bing Yan Cao in
Google Scholar
PubMed
Search for other papers by Yuan Ding in
Google Scholar
PubMed
Search for other papers by Jiayun Guo in
Google Scholar
PubMed
Search for other papers by Xiaoqiao Li in
Google Scholar
PubMed
Search for other papers by Xiaolin Ni in
Google Scholar
PubMed
Search for other papers by Zheng Yuan in
Google Scholar
PubMed
Search for other papers by Linqi Chen in
Google Scholar
PubMed
Search for other papers by Liyang Liang in
Google Scholar
PubMed
Search for other papers by Chunxiu Gong in
Google Scholar
PubMed
Objective: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, and autonomic dysregulation (ROHHAD) is rare, and manifestations of autonomic dysregulation are diverse and may be overlooked. We aimed to evaluate the incidence of these manifestations.
Methods: Patients with ROHHAD syndrome reported before and after 2019 were divided into Groups 1 and 2. Patients who were diagnosed at three regional hospitals in China were included in Group 3. We collected the age of each specific term of the ROHHAD (neurogenic tumor, NET) acronym and the detailed manifestations of each term, and compared them among the three groups.
Results: A total of 16 patients were diagnosed within the 2-year period. Two had neurogenic tumors and cognitive and behavioral abnormalities before developing rapid obesity. At least 93.8% of the patients had ≥ 4 symptoms of autonomic dysregulation. When comparing autonomic dysregulation among Groups 1–3, the rates of cardiovascular manifestations were NA vs. 12.8% vs. 81.2%; gastrointestinal disturbances were 11.4% vs. 8.5% vs. 62.5%; strabismus was 25.7% vs. 12.8% vs. 62.5%; sleep disturbance was NA vs. 6.4% vs. 50.0%; and abnormal pain threshold was NA vs. 10.6% vs. 25.0% (all p<0.05). The rates of cognitive and behavioral abnormalities were NA vs 29.8% and 87.5% (p<0.01).
Conclusions: Rapid-onset obesity is not always the first sign of ROHHAD syndrome. Higher rates of autonomic dysregulation and cognitive and behavioral abnormalities with multiple manifestations of autonomic dysregulation coexisted in our cohort, indicating that evaluations of autonomic function and the limbic system should be strengthened when assessing this condition.